FAST BioMedical Announces Successful Completion of Open-Labe

FAST BioMedical Announces Successful Completion of Open-Label Proof-of-Concept Study for Measuring Interstitial Volume


May 20, 2021
INDIANAPOLIS (May 21, 2021) — FAST BioMedical, a privately held, late-clinical-stage medical technology company, today announces the completion of an open-label study using its technology in chronic dialysis patients. The goal of the study was to use FAST BioMedical’s technology to determine total volume removal before and after dialysis treatment by measuring both plasma volume and interstitial volume.
 
Conducted at the Richard L. Roudebush VA Medical Center in Indianapolis, the study evaluated the safety, tolerability and performance of the FAST Technology in chronic dialysis patients with extremely reduced or no kidney function. Based on how FAST BioMedical’s technology works, this was the best initial patient population to establish clinical Proof-of-Concept.

Related Keywords

Dan Meier , Arjund Sinha , Richardl Roudebush Va Medical Center , Indiana Biosciences Research Institute , இந்தியானா உயிர் அறிவியல் ஆராய்ச்சி நிறுவனம் ,

© 2025 Vimarsana